Standard

Treatment of BRAFv600e positive anaplastic thyroid carcinoma : Case report. / Nikiforovich, Petr A.; Rumiantsev, Pavel A.; Sleptsov, Ilya V.; Ustinova, Tatiana V.; Slashchuk, Konstantin Yu; Vorobyev, Sergey L.; Serzhenko, Sergey S.; Abrosimov, Alexandr Yu; Kudryavtseva, Anna V.; Semenov, Arseny A.; Chernikov, Roman A.; Polyakov, Andrey P.; Fedenko, Alexander A.; Bolotina, Larisa V.; Paychadze, Anna A.; Trushin, Alexandr Y.; Kaprin, Andrey D.; Zakharova, Galina S.

в: Siberian Journal of Oncology, Том 19, № 5, 2020, стр. 131-144.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Nikiforovich, PA, Rumiantsev, PA, Sleptsov, IV, Ustinova, TV, Slashchuk, KY, Vorobyev, SL, Serzhenko, SS, Abrosimov, AY, Kudryavtseva, AV, Semenov, AA, Chernikov, RA, Polyakov, AP, Fedenko, AA, Bolotina, LV, Paychadze, AA, Trushin, AY, Kaprin, AD & Zakharova, GS 2020, 'Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report', Siberian Journal of Oncology, Том. 19, № 5, стр. 131-144. https://doi.org/10.21294/1814-4861-2020-19-5-131-144

APA

Nikiforovich, P. A., Rumiantsev, P. A., Sleptsov, I. V., Ustinova, T. V., Slashchuk, K. Y., Vorobyev, S. L., Serzhenko, S. S., Abrosimov, A. Y., Kudryavtseva, A. V., Semenov, A. A., Chernikov, R. A., Polyakov, A. P., Fedenko, A. A., Bolotina, L. V., Paychadze, A. A., Trushin, A. Y., Kaprin, A. D., & Zakharova, G. S. (2020). Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report. Siberian Journal of Oncology, 19(5), 131-144. https://doi.org/10.21294/1814-4861-2020-19-5-131-144

Vancouver

Nikiforovich PA, Rumiantsev PA, Sleptsov IV, Ustinova TV, Slashchuk KY, Vorobyev SL и пр. Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report. Siberian Journal of Oncology. 2020;19(5):131-144. https://doi.org/10.21294/1814-4861-2020-19-5-131-144

Author

Nikiforovich, Petr A. ; Rumiantsev, Pavel A. ; Sleptsov, Ilya V. ; Ustinova, Tatiana V. ; Slashchuk, Konstantin Yu ; Vorobyev, Sergey L. ; Serzhenko, Sergey S. ; Abrosimov, Alexandr Yu ; Kudryavtseva, Anna V. ; Semenov, Arseny A. ; Chernikov, Roman A. ; Polyakov, Andrey P. ; Fedenko, Alexander A. ; Bolotina, Larisa V. ; Paychadze, Anna A. ; Trushin, Alexandr Y. ; Kaprin, Andrey D. ; Zakharova, Galina S. / Treatment of BRAFv600e positive anaplastic thyroid carcinoma : Case report. в: Siberian Journal of Oncology. 2020 ; Том 19, № 5. стр. 131-144.

BibTeX

@article{1bcf30f79f634613914a37f4e1c62d28,
title = "Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report",
abstract = "Anaplastic thyroid cancer is one of the most aggressive and fatal human carcinomas. A significant experience in using various kinase inhibitors for anaplastic thyroid cancer therapy has been accumulated worldwide. The most encouraging results were obtained after using a combination of b-Raf and ME K kinase inhibitors (vemurafenib/dabrafenib and trametinib/cobimetinib, respectively) for the treatment of the unresectable BRAFV600E-positive anaplastic thyroid cancer. This drug combination makes it possible to perform surgery followed by chemoradiotherapy and other targeted therapies. Here we report a clinical case of anaplastic thyroid cancer in a 69-year-old woman, who was treated with neoadjuvant targeted therapy. The treatment was carried out on the basis of three medical institutions: The National Medical Research Radiological Centre (Moscow), the N.I. Pirogov Clinic of Advanced Medical Technologies (St. Petersburg) and the Endocrinology Research Center (Moscow). Since there is still no universal protocol for treating ATC patients, and only palliative therapy is used in most cases, we emphasized on diagnostic and treatment errors of this disease. Special attention was paid to the importance of using molecular diagnostics and modern medical imaging technologies.",
keywords = "Anaplastic thyroid cancer, BRAF mutation, Neoadjuvant therapy, Targeted therapy",
author = "Nikiforovich, {Petr A.} and Rumiantsev, {Pavel A.} and Sleptsov, {Ilya V.} and Ustinova, {Tatiana V.} and Slashchuk, {Konstantin Yu} and Vorobyev, {Sergey L.} and Serzhenko, {Sergey S.} and Abrosimov, {Alexandr Yu} and Kudryavtseva, {Anna V.} and Semenov, {Arseny A.} and Chernikov, {Roman A.} and Polyakov, {Andrey P.} and Fedenko, {Alexander A.} and Bolotina, {Larisa V.} and Paychadze, {Anna A.} and Trushin, {Alexandr Y.} and Kaprin, {Andrey D.} and Zakharova, {Galina S.}",
note = "Publisher Copyright: {\textcopyright} 2020, Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
doi = "10.21294/1814-4861-2020-19-5-131-144",
language = "English",
volume = "19",
pages = "131--144",
journal = "СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ",
issn = "1814-4861",
publisher = "Томский национальный исследовательский медицинский центр Российской академии наук",
number = "5",

}

RIS

TY - JOUR

T1 - Treatment of BRAFv600e positive anaplastic thyroid carcinoma

T2 - Case report

AU - Nikiforovich, Petr A.

AU - Rumiantsev, Pavel A.

AU - Sleptsov, Ilya V.

AU - Ustinova, Tatiana V.

AU - Slashchuk, Konstantin Yu

AU - Vorobyev, Sergey L.

AU - Serzhenko, Sergey S.

AU - Abrosimov, Alexandr Yu

AU - Kudryavtseva, Anna V.

AU - Semenov, Arseny A.

AU - Chernikov, Roman A.

AU - Polyakov, Andrey P.

AU - Fedenko, Alexander A.

AU - Bolotina, Larisa V.

AU - Paychadze, Anna A.

AU - Trushin, Alexandr Y.

AU - Kaprin, Andrey D.

AU - Zakharova, Galina S.

N1 - Publisher Copyright: © 2020, Tomsk National Research Medical Center of the Russian Academy of Sciences. All rights reserved. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020

Y1 - 2020

N2 - Anaplastic thyroid cancer is one of the most aggressive and fatal human carcinomas. A significant experience in using various kinase inhibitors for anaplastic thyroid cancer therapy has been accumulated worldwide. The most encouraging results were obtained after using a combination of b-Raf and ME K kinase inhibitors (vemurafenib/dabrafenib and trametinib/cobimetinib, respectively) for the treatment of the unresectable BRAFV600E-positive anaplastic thyroid cancer. This drug combination makes it possible to perform surgery followed by chemoradiotherapy and other targeted therapies. Here we report a clinical case of anaplastic thyroid cancer in a 69-year-old woman, who was treated with neoadjuvant targeted therapy. The treatment was carried out on the basis of three medical institutions: The National Medical Research Radiological Centre (Moscow), the N.I. Pirogov Clinic of Advanced Medical Technologies (St. Petersburg) and the Endocrinology Research Center (Moscow). Since there is still no universal protocol for treating ATC patients, and only palliative therapy is used in most cases, we emphasized on diagnostic and treatment errors of this disease. Special attention was paid to the importance of using molecular diagnostics and modern medical imaging technologies.

AB - Anaplastic thyroid cancer is one of the most aggressive and fatal human carcinomas. A significant experience in using various kinase inhibitors for anaplastic thyroid cancer therapy has been accumulated worldwide. The most encouraging results were obtained after using a combination of b-Raf and ME K kinase inhibitors (vemurafenib/dabrafenib and trametinib/cobimetinib, respectively) for the treatment of the unresectable BRAFV600E-positive anaplastic thyroid cancer. This drug combination makes it possible to perform surgery followed by chemoradiotherapy and other targeted therapies. Here we report a clinical case of anaplastic thyroid cancer in a 69-year-old woman, who was treated with neoadjuvant targeted therapy. The treatment was carried out on the basis of three medical institutions: The National Medical Research Radiological Centre (Moscow), the N.I. Pirogov Clinic of Advanced Medical Technologies (St. Petersburg) and the Endocrinology Research Center (Moscow). Since there is still no universal protocol for treating ATC patients, and only palliative therapy is used in most cases, we emphasized on diagnostic and treatment errors of this disease. Special attention was paid to the importance of using molecular diagnostics and modern medical imaging technologies.

KW - Anaplastic thyroid cancer

KW - BRAF mutation

KW - Neoadjuvant therapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85096223446&partnerID=8YFLogxK

U2 - 10.21294/1814-4861-2020-19-5-131-144

DO - 10.21294/1814-4861-2020-19-5-131-144

M3 - Article

AN - SCOPUS:85096223446

VL - 19

SP - 131

EP - 144

JO - СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ

JF - СИБИРСКИЙ ОНКОЛОГИЧЕСКИЙ ЖУРНАЛ

SN - 1814-4861

IS - 5

ER -

ID: 75570338